Generate Biomedicines

GENB

Capitalización de mercado USD 1552 M

Collaboration will combine Zealand Pharma's expertise in metabolic health with Generate's proprietary generative AI platform to create multispecific drug candidates with tailored biological functions

Press release – No. 20 / 2026 Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases Collaboration will combine Zealand Pharma's expertise in metabolic health with Generate's proprietary generative AI platform to create multispecific drug candidates with tailored biological functions Generate will receive USD 30 million up-front, up to USD 35 million in early preclinical milestones, and a total of nearly USD 1.2 billion in milestones, plus tiered royalties for two initial programs, with an option to add a third The agreement will broaden Zealand Pharma's modality capabilities beyond peptides while extending The Generate Platform into obesity and other metabolic diseases Copenhagen, Denmark, October 13, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.

Generate Biomedicines offers a compelling long-acting asthma biologic, golukibart (GB-0895), targeting twice-yearly dosing and broad phenotype efficacy. GENB leads the TSLP antagonist race with two global Phase 3 trials underway, aiming to displace Tezspire and capitalize on significant asthma and COPD market upside. Cash runway extends into early 2028, but Phase 3 trial costs and potential dilution before topline data are key risks to monitor.

Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trials First patient treated in new clinical trial underway at Roswell Park Treatment is designed to avoid pre-infusion chemotherapy and its side effects GB-5267 targets MUC16, a biomarker over-expressed in +80% of ovarian tumors BUFFALO, N.Y. and SOMERVILLE, Mass.

Generate Biomedicines, Inc. (GENB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

SOMERVILLE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Generate Biomedicines Inc. (Nasdaq: GENB) (“Generate”) today announced that members of its management team will participate in presentations at the following investor conferences:

Shares of Generate Biomedicines Inc (NASDAQ:GENB) jumped more than 20% on Tuesday as investors positioned ahead of the expiration of the company's post-IPO lock-up period. The lock-up, which ends Wednesday, will free company insiders, early investors and major shareholders to sell shares issued as part of Generate's $400 million initial public offering earlier this year, which included 25 million shares.

SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 studies for GB-0895 (anti-TSLP) in severe asthma continue to advance with recruitment underway across all six global regions Phase 1b data for GB-0895 in COPD to be presented in a poster at the European Respiratory Society (ERS) Congress 2026 on Sept. 8 All patients enrolled in first cohort of the Phase 1 study for GB-4362 (MMAE neutralizer) Platform advancements extend across strategic collaborations Approximately $457.4 million in cash, cash equivalents, and marketable securities as of June 30, 2026 SOMERVILLE, Mass.

Generate Biomedicines had its IPO this past February. The company has had buy-in from Nvidia and Amgen.

The chipmaker has active interests in the healthcare market, including a partnership with Eli Lilly and an investment in small biotech Generate Biomedicines. Nvidia CEO Jensen Huang sees a powerful intersection between health and AI.